1/30,盐野义(Shionogi)周四宣布,其在研呼吸道合胞病毒(RSV)抗病毒药物在 II 期临床试验中达到主要终点,相较于安慰剂,显著降低了病毒载量。 该候选药物 S-337395 是一种口服 L 蛋白抑制剂,由盐野义与 UBE Corporation 共同开发。其中,盐野义负责全球临床开发,而 UBE 负责活性药物成分(API)的生产。S-337395 已...
It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for ...
Shionogi: Good results in phase 2 clinical trials of the drug S-337395 for treating RS virus infections Jan 30 14:30 Shionogi: Acceptance of a New Drug Application for the COVID-19 Treatment, Ensitrelvir Fumaric Acid, in Taiwan and Conclusion of Government Stockpiling Contract Jan 22 10:30...